| 摘要 |
FIELD: medicine. ^ SUBSTANCE: medications containing hydroxyapatite and active components for transcutaneous and/or transmucous delivery are claimed. Maximum size of hydroxyapatite particles is 1 mcm or less, preferably 0.1 mcm or less, and hydroxyapatite content included in composition comprises 0.1 to 1000 wt % of medication weight. ^ EFFECT: excellent amplification effect on transcutaneous and/or transmucous suction of active components applied onto skin or mucosa. ^ 24 cl, 11 tbl, 15 ex |
